Skip to main navigation menu Skip to main content Skip to site footer

Fosfolipoproteinosis alveolar. 10 casos 12 años de experiencia

Fosfolipoproteinosis alveolar. 10 casos 12 años de experiencia




Section
Research article

How to Cite
Fosfolipoproteinosis alveolar. 10 casos 12 años de experiencia.
rev. colomb. neumol. [Internet]. 2004 Mar. 1 [cited 2024 Dec. 22];16(1):8-13.

DOI
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Ricardo Durán Acuña

    Ricardo Durán Acuña,

    Jefe unidad de neumología Hospital de San José. 


    Because Pulmonary Alveolar Proteinosis (PA), is a rare disease, 12 years has been necessary to pass by, to diagnose 10 cases of the disease, and to realized 24 whole lung lavages in these 10 patients. The disease is characterized by de accumulation of lipoproteinaceous material in the alveoli, that could cause a progressive respiratory failure, that results from de impaired gas exchange in the alveolus, and a complete alteration of the mechanical ventilation of the respiratory tract.
    In this article we discuss our experience with 10 patients with a confirmed diagnosis of Pulmonary Alveolar Poteinosis, and a review of the recent medical literature publications. 


    Article visits 0 | PDF visits 0


    Downloads

    Download data is not yet available.
    1. Daphne E. De Mello. Pulmonary Alveolar Proteinosis : A Review. Pediatric Pathology and Molecular Medicine 2001;20:413 —432.
    2. James L. Knott, etal. Pulmonary Alveolar Proteinosis. Annals of Internal Medicine 2001; Sept 1961; Vol 55 ,N 3 : 481- 490.
    3. Mani S. Kavuru .- Marc popovich. Therapeutic Whole Lung Lavage : A Stop Gap therapy for Alveolar Proteinosis. Chest Oct, 2002; Vol 122 N 4: 1-2. i
    4. Yoshioca Y. Increased Circulating CD 16 + CD 14dim mono- cytes in a patient with Pulmonary Alveolar Proteinosis. Respirology - Sept 2002; 01: 273-279.
    5. Jean S. Bussiéres. Whole Lung Lavage. Anesthesiology Clinics Of North America, Sept 2001; Vol 19 , N 3: 1- 10.
    6. Bonfield TL , et al. Anti GM-CSF Titer Predicts response to GM-CSF Therapy in Pulmonary Alveolar Proteinosis. Clinical Inmunology , Dec 2002; 105 ( 3 ): 342- 350.
    7. Arbiser ZK. Guidot DM, et al. Pulmonary Alveolar Proteinosis mimiking Idiopathic Pulmonary Fibrosis. Annals Of Diagnostic Pathology, Apr 2003; 7(2):82-86.
    8. Hashizume T. Pulmonary Alveolar Proteinosis Successfully treated with Ambroxol. Internal Medicine, Dec 2002, 41 (12): 1175-1178.
    9. Shih-Lung Cheng. et al. Pulmonary Alveolar Proteinosis: Treat- ment By Bronchofiberscopic Lobar Lavage.Chest, Oct 2002; 122(4):1480-1484.
    Sistema OJS 3.4.0.7 - Metabiblioteca |